Novartis subsidiary Sandoz's antibiotics efforts bear fruit during pandemic

Sandoz stands out from other pharmaceutical companies, as it produces both the active ingredients for antibiotics and the finished product. This is a strategy that served the company well during the pandemic, says Chief Business Officer Carol Lynch.
Photo: Sandoz / PR
Photo: Sandoz / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT

The pandemic has been a blessing and a curse for Sandoz's antibiotics business.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading